Abstract
PURPOSE In the phase 3 KEYNOTE-407 study, the addition of pembrolizumab to carboplatin-paclitaxel/ nab-paclitaxel significantly improved overall survi......
小提示:本篇文献需要登录阅读全文,点击跳转登录